JapanHealthcare and life sciences2023 – ongoingTakeda Pharmaceutical
myAibou in-house generative AI assistant
More than 24,000 Takeda employees have used its in-house AI assistant myAibou
Problem
Takeda wanted employees to build generative AI skills and have a safe tool for everyday tasks. Leaders were concerned that private company data could be made public through public AI tools.
Approach
Two Takeda staff discussed building an assistant in early February 2023, and a prototype was ready the following week. myAibou drafts emails, analyses content, drafts presentation decks and organises calendars. It has no access to Takeda data beyond what a user enters. It was rolled out gradually to larger groups, and by mid-2024 Takeda was on version 2.0, with meeting review planned next.
Results
Takeaway
Takeda started from a quick prototype and widened access in stages, and usage passed 24,000 employees within about two years.
Categories
- Size
- Large enterprise
- Industry
- Healthcare and life sciences
- Business function
- Internal work and knowledge management
- Innovation type
- Process innovation
- AI technology
- Generative AI
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Fortune described myAibou as a generative AI chatbot introduced as part of Takeda's upskilling push. It reported that more than 24,000 employees had used it for summarising, content creation and other routine tasks.
Takeda told the origin of myAibou: a prototype in February 2023 and a gradual rollout. It described the tasks it supports and its data privacy design. It said version 2.0 was already in use and the next version would focus on meetings. It gave no usage numbers.
Full details are in the original sources.